Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.
This is written in the approval document as:
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Letrozole | |
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Letrozole | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Letrozole |